Company: PRME
Filing Date: 2025-11-07
Form Type: S-3ASR
Source: 0001628280-25-050428
Chunk: 71

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: S-3ASR
Chunk 71
---
ORPORATION OF CERTAIN INFORMATION BY REFERENCE
The SEC allows us to incorporate by reference in this prospectus much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below, which we have already filed with the SEC (Commission File No. 001-41536), and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including all filings made after the date of the filing and concurrent effectiveness of the registration statement, except as to any portion of any future report or document that is not deemed filed under such provisions, until the offering of the securities made by this prospectus is completed or terminated:

• Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 28, 2025 ;

• The information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December 31, 2024 from our definitive proxy statement on Schedule 14A (other than information furnished rather than filed), which was filed with the SEC on April 22, 2025 ;

• Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, filed with the SEC on May 8, 2025 , August 7, 2025 and November 7 , 2025 , respectively;

• Current Reports on Form 8-K filed with the SEC on March 18, 2025 , May 19, 2025 , June 5, 2025 , July 15, 2025 , July 30, 2025 , July 31, 2025 , and August 5, 2025 ; and

• The description of our common stock